End-to-end Peptide Discovery
Solutions
By leveraging Isogenica’s proprietary CIS Display™ technology and synthetic libraries alongside Charles River Laboratories’ proficiency in early-stage discovery services, we offer biotechnology companies an optimized and efficient pathway from initial peptide hit identification to lead optimization and further development.
Accelerating Peptide Therapeutics
Biotech companies regularly encounter challenges for the advancement of peptide therapeutics. Fragmented workflows extend timelines and elevate costs, while vast standalone projects lack the agility to change course as the research progresses. Additionally, uncertainty often surrounds the process of translating hits into clinical success.
Our collaboration effectively addresses these obstacles by integrating Isogenica’s extensive expertise in peptide libraries and CIS Display™ technology with Charles River Laboratories’ comprehensive early-stage discovery services. Together, the partnership offers a streamlined solution that expedites the journey from hit identification to clinical validation.
Peptides – Displayed Differently
- 8x off-the-shelf libraries, or build your own
- Choose from 8-16 variable positions
- Linear or constrained, with beta turns available
- CIS Display™ – ultimate scalability for
challenging targets or precise conditions. - Validated since 2004 for peptide discovery